ArticleFrontiers in oncology2026
Network analysis of core symptom changes in hepatocellular carcinoma survivors after transarterial chemoembolization: A longitudinal study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aims of this study were to explore the longitudinal trajectories of core symptoms in survivors with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) and to analyze their associations with health-related quality of life (HRQoL) and unmet supportive care needs. Methods: This longitudinal study enrolled 271 HCC survivors undergoing TACE in China. Patient-reported outcomes were assessed at three time points-24 h (T1), 7 days (T2), and 1 month (T3) post-TACE-using four validated instruments: the MD Anderson Symptom Inventory-Chinese Version (MDASI-C), the Tumor Symptom Measure for Primary Liver Cancer (TSM-PLC), the Quality of Life Instrument for Liver Cancer (QOL-LC V2.0), and the Short Form of Survivors' Unmet Needs Scale (SF-SUNS). Exploratory factor analysis was conducted to extract discrete symptom clusters, and network analysis was used to calculate strength centrality (rs)-an index quantifying the sum of absolute edge weights connecting each symptom to all others-to identify core symptoms. Results: Five symptom clusters were identified at T1: Fatigue-Cognitive, Post-embolization, Somatic, Emotional, and Hepatobiliary-Specific. The Post-embolization cluster was present only at T1, whereas the remaining four clusters persisted at T2 and T3. However, the core symptom shifted over time: nausea at T1 (rs = 1.154), lack of appetite at T2 (rs = 1.229), and sadness at T3 (rs = 1.107). HRQoL was lowest at T1, improved at T2, and declined at T3, with all pairwise comparisons significant (all Conclusions: During the first month post-TACE, the sequence of core symptoms transitioned from nausea to lack of appetite and then to sadness, suggesting time-specific supportive care strategies-including antiemetic prophylaxis, nutritional support, and psychosocial care. Routine assessment of unmet needs may help reduce symptom burden and optimize long-term HRQoL for these survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.